全文获取类型
收费全文 | 1629篇 |
免费 | 153篇 |
国内免费 | 45篇 |
专业分类
儿科学 | 142篇 |
妇产科学 | 10篇 |
基础医学 | 96篇 |
口腔科学 | 1篇 |
临床医学 | 115篇 |
内科学 | 50篇 |
皮肤病学 | 5篇 |
神经病学 | 312篇 |
特种医学 | 7篇 |
外科学 | 44篇 |
综合类 | 369篇 |
预防医学 | 80篇 |
眼科学 | 1篇 |
药学 | 148篇 |
1篇 | |
中国医学 | 413篇 |
肿瘤学 | 33篇 |
出版年
2024年 | 5篇 |
2023年 | 20篇 |
2022年 | 42篇 |
2021年 | 66篇 |
2020年 | 72篇 |
2019年 | 47篇 |
2018年 | 30篇 |
2017年 | 46篇 |
2016年 | 52篇 |
2015年 | 53篇 |
2014年 | 123篇 |
2013年 | 97篇 |
2012年 | 118篇 |
2011年 | 84篇 |
2010年 | 69篇 |
2009年 | 90篇 |
2008年 | 63篇 |
2007年 | 86篇 |
2006年 | 53篇 |
2005年 | 45篇 |
2004年 | 53篇 |
2003年 | 60篇 |
2002年 | 40篇 |
2001年 | 37篇 |
2000年 | 26篇 |
1999年 | 25篇 |
1998年 | 20篇 |
1997年 | 21篇 |
1996年 | 21篇 |
1995年 | 12篇 |
1994年 | 11篇 |
1993年 | 18篇 |
1992年 | 16篇 |
1991年 | 14篇 |
1990年 | 14篇 |
1989年 | 7篇 |
1988年 | 13篇 |
1987年 | 4篇 |
1986年 | 15篇 |
1985年 | 12篇 |
1984年 | 24篇 |
1983年 | 18篇 |
1982年 | 15篇 |
1981年 | 16篇 |
1980年 | 13篇 |
1979年 | 11篇 |
1978年 | 5篇 |
1977年 | 6篇 |
1973年 | 3篇 |
1972年 | 5篇 |
排序方式: 共有1827条查询结果,搜索用时 31 毫秒
81.
82.
Gianluca Marucci Marco Giulioni Guido Rubboli Michela Paradisi Mercedes Fernández Giovanna Del Vecchio Eugenio Pozzati 《Clinical neurology and neurosurgery》2013
Objective
The relationship between hippocampal histopathological abnormalities, epileptogenesis and neurogenesis remains rather unclear.Methods
Tissue samples including the subgranular zone of dentate gyrus (DG) were freshly collected for tissue culture for neurospheres generation in 16 patients who underwent surgery for drug-resistant temporal lobe epilepsy. Remaining tissues were histologically examined to assess the presence of mesial temporal sclerosis (MTS) and focal cortical dysplasia.Results
MTS was detected in 8 cases. Neurospheres were formed in 10/16 cases. Only three out of these 10 cases exhibited MTS; on the contrary 5/6 cases lacking neurosphere proliferation presented MTS. There was a significant correlation between presence of MTS and absence of proliferation (p = 0.0389). We also observed a correlation between history of febrile seizures (FS) and presence of MTS (p = 0.0004) and among the 6 cases lacking neurosphere proliferation, 4 cases (66.6%) had experienced prolonged FS. Among “proliferating” cases the percentage of granular cells pathology (GCP) was lower (20% vs 50%) compared to “non proliferating” cases.Conclusion
A decreased potential to generate neurosphere from the SGZ is related to MTS and to alterations of dentate gyrus granule cells, especially in MTS type 1b and GCP type 1. These histological findings may have different prognostic implications, regarding seizure and neuropsychological outcome, compared to patients with other epileptogenic lesions (such as FCD, glioneuronal tumours, vascular lesions). 相似文献83.
Atsushi Ishii Sawa Yasumoto Yukiko Ihara Takahito Inoue Takako Fujita Noriko Nakamura Masaharu Ohfu Yushiro Yamashita Hideo Takatsuka Toshiaki Taga Rie Miyata Masahiro Ito Hiroshi Tsuchiya Taro Matsuoka Tetsuya Kitao Kiyotaka Murakami Wang-Tso Lee Sunao Kaneko Shinichi Hirose 《Brain & development》2013
Purpose: PRRT2 mutations were recently identified in benign familial infantile epilepsy (BFIE) and infantile convulsions with paroxysmal choreoathetosis (ICCA) but no abnormalities have so far been identified in their phenotypically similar seizure disorder of benign convulsions with mild gastroenteritis (CwG), while mutations in KCNQ2 and KCNQ3 have been recognized in benign familial neonatal epilepsy (BFNE). The aim of this study was to identify PRRT2 mutations in infantile convulsions in Asian families with BFIE and ICCA, CwG and BFNE. Methods: We recruited 26 unrelated Japanese affected with either BFIE or non-familial benign infantile seizures and their families, including three families with ICCA. A total of 17 Japanese and Taiwanese with CwG, 50 Japanese with BFNE and 96 healthy volunteers were also recruited. Mutations of PRRT2 were sought using direct sequencing. Results: Heterozygous truncation mutation (c.649dupC) was identified in 15 of 26 individuals with benign infantile epilepsy (52.1%). All three families of ICCA harbored the same mutation (100%). Another novel mutation (c.1012+2dupT) was found in the proband of a family with BFIE. However, no PRRT2 mutation was found in either CwG or BFNE. Conclusions: The results confirm that c.649dupC, a truncating mutation of PRRT2, is a hotspot mutation resulting in BFIE or ICCA regardless of the ethnic background. In contrast, PRRT2 mutations do not seem to be associated with CwG or BFNE. Screening for PRRT2 mutation might be useful in early-stage differentiation of BFIE from CwG. 相似文献
84.
Ben Kang Dong Hyun Kim Young Jin Hong Byong Kwan Son Dong Wook Kim Young Se Kwon 《Seizure》2013,22(7):560-564
PurposeWe aimed on identifying the differences of febrile and afebrile seizures associated with mild rotavirus gastroenteritis (RVGE) in the pediatric population.MethodMedical charts of pediatric patients who had been admitted between July 1999 and June 2011 due to RVGE were retrospectively reviewed. Subjects were ultimately divided into three groups; ‘no seizure’ (NS: patients without seizure), ‘febrile seizure’ (FS: patients with fever during seizure), ‘afebrile seizure’ (AFS: patients without fever during seizure). Comparisons between groups were carried out on demographic and clinical characteristics, laboratory test results, electroencephalogram findings, brain magnetic resonance imaging findings, antiepileptic treatment, and prognosis.ResultsAmong the 755 subjects who had been admitted due to mild rotavirus enteritis, 696 (90.3%) did not have any seizures, 17 (2.2%) had febrile seizures, 42 (5.5%) had afebrile seizures. The duration of gastrointestinal symptoms before the onset of seizures were significantly shorter in the FS group compared to the AFS group (1.3 ± 0.8 vs. 2.8 ± 1.0 days; p < 0.0001). A single seizure attack was significantly higher in the AFS group (3.0 ± 1.6 vs. 1.7 ± 1.0 episodes; p = 0.0003), and the frequency of seizures that were of focal type with or without secondary generalization were significantly higher in the AFS group (33.3% vs. 6.0%; p = 0.0139). All patients among the FS and AFS group had not received further antiepileptic treatment after discharge, and none developed epilepsy during follow up period.ConclusionDespite some differences in seizure characteristics, both febrile and afebrile seizures associated with mild RVGE were mostly benign with a favorable prognosis. 相似文献
85.
《Brain & development》2022,44(3):210-220
ObjectiveBiomarkers predicting poor outcomes of status-epilepticus-associated-with-fever (SEF) at an early stage may contribute to treatment guidance. However, none have been reported thus far. We investigated the dynamics of serum growth and differentiation factor (GDF)-15 after seizure onset in patients with SEF and determined whether GDF-15 can predict poor outcomes, particularly in the first 6 h after seizure onset.MethodsWe enrolled 37 pediatric patients with SEF and eight patients with simple febrile seizures (SFS) and collected their blood samples within 24 h of seizure onset and eight febrile control patients between March 1, 2017 and September 30, 2020. All patients were aged ≤15 years.ResultsIn the SEF group, the median post-seizure serum GDF-15 values were 1,065 (<6h), 2,720 (6–12 h), and 2,411 (12–24 h) pg/mL. The median serum GDF-15 in the first 6 h was measured in patients with SEF without a significant past medical history (n = 21) and was found to be statistically significantly higher (1,587 pg/mL) than in the febrile control (551 pg/mL) and SFS (411 pg/mL) groups. The median serum GDF-15 was statistically significantly higher in patients with SEF with sequelae (n = 5) and patients with acute encephalopathy with biphasic seizures/reduced diffusion/hemorrhagic shock and encephalopathy syndrome (n = 6) than in patients with SEF without sequelae (n = 16) (15,898 vs 756 pg/mL) and patients with prolonged FS (n = 15) (9,448 vs 796 pg/mL).ConclusionsThis study demonstrates the dynamics of serum GDF-15 in patients with SEF and indicates the potential of GDF-15 as an early predictor of poor outcomes. 相似文献
86.
对患有神经系统疾病儿童进行疫苗接种决策对于人们尤其是儿科医生来说是个棘手的问题,医生和家长们担心出现不良反应(如惊厥、疫苗脑病等)或考虑患儿存在热敏感性惊厥疾病的病史,担心疫苗接种导致惊厥发作,从而倾向于不给或不推荐其接种疫苗,而热性惊厥、GEFS+、Dravet综合征这类热敏感性疾病是最常见的惊厥性疾病之一,其发病机制被证实多与SCN 钠离子亚通道基因突变导致功能缺失相关。对于FS、GEFS、以及Dravet综合征的患儿,疫苗接种可能会导致发热,引起惊厥,但疫苗接种并不会使他们的预后变差。 相似文献
87.
《The Journal of pharmacy and pharmacology》2018,70(9):1272-1286
Objectives
To investigate whether mice develop tolerance to the anxiolytic‐like and anticonvulsant effects of subchronic treatment with EA (the styryl‐2‐pyrones and dihydrostyryl‐2‐pyrones‐rich fraction of Polygala sabulosa ), as well as any withdrawal symptoms after abrupt discontinuation; to compare the effects of EA with those of diazepam (DZP ) on withdrawal‐induced anxiety; and to evaluate the toxicity of EA according to OECD guidelines.Methods
Male or female mice were acutely or subchronically treated with EA or DZP , and their tolerance to anxiolytic (evaluated in the elevated plus maze, EPM ) and anticonvulsant effects (measured against pentylenetetrazole (PTZ )‐induced convulsions) were investigated. Other groups received EA or DZP for 28 days followed by withdrawal, being the anxiety‐like behaviour evaluated in the EPM .Key findings
Both acute and subchronic treatments with EA induced an anxiolytic effect in the EPM . The anticonvulsant activity of DZP , but not EA , was reduced by protracted treatment. EA withdrawal retained the anxiolytic profile, while DZP withdrawal induced anxiogenesis. EA counteracted the anxiogenic‐like actions of DZP withdrawal. EA has low toxicity as it did not cause any changes in the biochemical, haematological and histopathological markers.Conclusions
EA avoids the development of tolerance to its anxiolytic‐like and anticonvulsant actions, and does not promote withdrawal syndrome. EA does not cause relevant toxic effects in rodents.88.
Derek Weycker Ahuva Hanau Alexander Lonshteyn Charles Bowers Mark Bensink Tamer Garawin 《Current medical research and opinion》2018,34(9):1705-1711
Background: Two recent evaluations reported that risk of febrile neutropenia (FN) may be higher when pegfilgrastim prophylaxis (PP) is administered on same day as chemotherapy rather than per recommendation (1–3 days following chemotherapy). Such evidence is based largely on the experience of younger privately insured adults and may not be generalizable to older patients in US clinical practice.Methods: A retrospective cohort design and data from Medicare Claims Research Identifiable Files (January 2008–September 2015) were employed. Patients were aged ≥65 years, had breast cancer or non-Hodgkin’s lymphoma, received chemotherapy with intermediate/high risk for FN, and received PP in ≥1 cycle; cycles with PP were stratified based on administration day (same-day [“Day 0”] vs. 1–3 days following chemotherapy [“Days 1–3”]) and were pooled for analyses. Adjusted odds ratios (ORs) for FN during the cycle were estimated for patients who received PP on Day 0 versus Days 1–3.Results: Study population included 65,003 patients who received PP in 261,184 cycles; in 5% of cycles, patients received PP on Day 0. Incidence proportion for FN in cycle 1 was 11.4% for Day 0 versus 8.4% for Days 1–3; adjusted OR was 1.4 (p?.001). Incidence proportion for FN when considering all cycles was 7.7% for Day 0 and 6.0% for Days 1–3; adjusted OR was 1.3 (p?.001). Adjusted ORs when considering all cycles and only inpatient FN episodes (1.3, p?.001) and the narrow definition for FN (1.5, p?.001) were similar.Conclusions: Among Medicare patients receiving chemotherapy and PP in US clinical practice, PP was administered before the recommended timing in 5% of cycles and FN incidence was significantly higher in these cycles. Along with prior research, study findings support recently updated US practice guidelines indicating that PP should be administered the day after chemotherapy. 相似文献
89.
90.